Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
National Defense Authorization Act for Fiscal Year 2024
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, national security, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; issues relating to pandemic preparedness and infectious disease education; issues relating to step therapy; issues relating to health care extenders; issues related to federal contracting relating to biopharmaceutical manufacturers
National Defense Authorization Act for Fiscal Year 2024
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2024 · second_quarter · Q2
Biodefense, FDA, national security, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; issues relating to pandemic preparedness and infectious disease education; issues relating to step therapy; issues relating to health care extenders; issues related to federal contracting relating to biopharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
Biodefense, FDA, national security, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; issues relating to pandemic preparedness and infectious disease education; issues relating to step therapy; issues relating to health care extenders; issues related to federal contracting relating to biopharmaceutical manufacturers
EPA Accountability to Farm Country Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; Biomedical Advanced Research and Development Authority contract; issues relating to step therapy
EPA Accountability to Farm Country Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; Consolidated Appropriations Act, 2023; issues related to the Prescription Drug User Fee Act
EPA Accountability to Farm Country Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; issues relating to step therapy
EPA Accountability to Farm Country Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; Biomedical Advanced Research and Development Authority contract; issues relating to step therapy; issues relating to development of COVID therapeutics; issues relating to health care extenders
Affordable Insulin Now Act of 2023
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; Biomedical Advanced Research and Development Authority contract; issues relating to step therapy
Affordable Insulin Now Act of 2023
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; issues relating to step therapy
Affordable Insulin Now Act of 2023
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; Consolidated Appropriations Act, 2023; issues related to the Prescription Drug User Fee Act
Inflation Reduction Act of 2022
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; Consolidated Appropriations Act, 2023; issues related to the Prescription Drug User Fee Act
Inflation Reduction Act of 2022
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022
Inflation Reduction Act of 2022
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
Food and Drug Amendments of 2022
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022
Food and Drug Amendments of 2022
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
National Defense Authorization Act for Fiscal Year 2023
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022
National Defense Authorization Act for Fiscal Year 2023
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
PREVENT Pandemics Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
FDASLA Act of 2022
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
FDASLA Act of 2022
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022
Elijah E. Cummings Lower Drug Costs Now Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Medicare issues relating to biopharmaceutical manufacturers; Medicare and Medicaid payment policies; bills relating to drug pricing and Medicare Part B including H.R. 3 and S. 2543
Prescription Drug Pricing Reduction Act of 2019
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Medicare issues relating to biopharmaceutical manufacturers; Medicare and Medicaid payment policies; bills relating to drug pricing and Medicare Part B including H.R. 3 and S. 2543
Affordable and Safe Prescription Drug Importation Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, issues relating to drug importation; Affordable Care Act reform proposals; issues relating to the FDA.
Affordable and Safe Prescription Drug Importation Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, issues relating to drug importation; Affordable Care Act reform proposals; issues relating to the FDA.
Affordable and Safe Prescription Drug Importation Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, issues relating to drug importation; Affordable Care Act reform proposals.
Affordable and Safe Prescription Drug Importation Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, issues relating to drug importation; Affordable Care Act reform proposals.
Affordable and Safe Prescription Drug Importation Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, issues relating to drug importation; Affordable Care Act reform proposals; issues relating to the FDA.
Affordable and Safe Prescription Drug Importation Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, issues relating to drug importation; Affordable Care Act reform proposals; issues relating to the FDA.
21st Century Cures Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Issues relating to bio-preparedness; issues relating to innovation; H.R.6 - 21st Century Cures Act; FDA issues relating to biopharmaceuticals.
21st Century Cures Act
Client: REGENERON PHARMACEUTICALS, INC · Firm: REGENERON PHARMACEUTICALS, INC
Issues relating to Medicare; issues relating to bio-preparedness; issues relating to innovation; H.R.6 - 21st Century Cures Act.
2024 · first_quarter · Q1
Biodefense, FDA, national security, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024; issues relating to pandemic preparedness and infectious disease education; issues relating to step therapy; issues relating to health care extenders; issues related to federal contracting relating to biopharmaceutical manufacturers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2023 · fourth_quarter · Q4
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; Biomedical Advanced Research and Development Authority contract; issues relating to step therapy; issues relating to development of COVID therapeutics; issues relating to health care extenders
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2023 · third_quarter · Q3
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; Biomedical Advanced Research and Development Authority contract; issues relating to step therapy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2023 · second_quarter · Q2
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; issues relating to the Inflation Reduction Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; issues relating to the Prescription Drug User Fee Act; issues relating to infectious disease education; issues relating to the Pandemic and All-Hazards Preparedness reauthorization; issues relating to step therapy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2023 · first_quarter · Q1
Biodefense, FDA, and privacy issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing and pricing; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.954 - Affordable Insulin Now Act of 2023; Consolidated Appropriations Act, 2023; issues related to the Prescription Drug User Fee Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2022 · fourth_quarter · Q4
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022; S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats, (PREVENT) and Pandemics Act; Consolidated Appropriations Act, 2023
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2022 · third_quarter · Q3
Patent issues relating to biopharmaceutical manufacturers; intellectual property rights
Biodefense and FDA issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, step therapy, TRIPS waivers, and pricing; pandemic response measures, including manufacturing and budget appropriation issues; H.R.5376 - Inflation Reduction Act of 2022; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023; S.4348 - FDASLA Act of 2022, H.R.7667 - Food and Drug Amendments of 2022
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2022 · second_quarter · Q2
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, and pricing; pandemic response measures, including manufacturing and budget appropriation issues
Patent issues relating to biopharmaceutical manufacturers; intellectual property rights
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2022 · first_quarter · Q1
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, and pricing; pandemic response measures, including manufacturing and budget appropriation issues
Patent issues relating to biopharmaceutical manufacturers; intellectual property rights
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2021 · fourth_quarter · Q4
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, and pricing; pandemic response measures, including manufacturing and budget appropriation issues
Medicare and Medicaid issues relating to biopharmaceutical manufacturers, including ancillary care
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2021 · third_quarter · Q3
Medicare and Medicaid issues relating to biopharmaceutical manufacturers, including ancillary care
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, and pricing; pandemic response measures, including manufacturing and budget appropriation issues
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2021 · second_quarter · Q2
Medicare and Medicaid issues relating to biopharmaceutical manufacturers, including ancillary care
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, and pricing; pandemic response measures, including manufacturing and budget appropriation issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2021 · first_quarter · Q1
Medicare and Medicaid issues relating to biopharmaceutical manufacturers, including ancillary care
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, and pricing; pandemic response measures, including manufacturing and budget appropriation issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2020 · fourth_quarter · Q4
Medicare and Medicaid issues relating to biopharmaceutical manufacturers, including ancillary care
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing, access, and pricing; pandemic response measures, including manufacturing and budget appropriation issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2020 · third_quarter · Q3
Medicare and Medicaid issues relating to biopharmaceutical manufacturers
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing; pandemic response measures, including manufacturing and budget appropriation issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of the Vice President of the United States, SENATE, White House Office
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2020 · second_quarter · Q2
Patent issues relating to biopharmaceutical manufacturers; intellectual property rights
Biodefense issues relating to biopharmaceutical manufacturers; tax and incentives; issues related to drug manufacturing; pandemic response measures
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2020 · first_quarter · Q1
Patent issues relating to biopharmaceutical manufacturers; intellectual property rights
Medicare issues relating to biopharmaceutical manufacturers; Medicare and Medicaid payment policies; bills relating to drug pricing and Medicare Part B including H.R. 3 and S. 2543
Biodefense issues relating to biopharmaceutical manufacturers; pandemic readiness and response
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of the Vice President of the United States, SENATE, White House Office
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2019 · fourth_quarter · Q4
Patent issues relating to biopharmaceutical manufacturers.
Medicare issues relating to biopharmaceutical manufacturers; Medicare and Madicaid payment policies; drug pricing
Bio-defense issues relating to bio-pharmaceutical manufacturers; issues related to opioids; issues related to biopharmceutical sector, innovation, patient access and health care manufacturing; issues related to healthcare reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2019 · third_quarter · Q3
Issues relating to bio-preparedness; Regulatory and appropriations issues relating to HHS; Issues relating to prescription drug pricing and payment reforms.
Medicare issues relating to biopharmaceutical manufacturers.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2019 · second_quarter · Q2
Medicare issues relating to biopharmaceutical manufacturers.
Issues relating to bio-preparedness; Regulatory issues relating to the FDA; Issues relating to prescription drug pricing and payment reforms.
Tax issues related to biopharmaceutical manufacturers.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2019 · first_quarter · Q1
Issues relating to bio-preparedness; Regulatory issues relating to the FDA; Issues relating to prescription drug pricing and payment reforms.
Tax issues related to biopharmaceutical manufacturers.
Medicare issues relating to biopharmaceutical manufacturers.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2018 · fourth_quarter · Q4
Tax issues related to biopharmaceutical manufacturers.
Medicare issues relating to biopharmaceutical manufacturers.
Issues relating to bio-preparedness; Regulatory issues relating to the FDA; Issues relating to prescription drug pricing and payment reforms.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2018 · third_quarter · Q3
Medicare issues relating to biopharmaceutical manufacturers.
Tax issues related to biopharmaceutical manufacturers.
Regulatory issues relating to the FDA; Issues relating to prescription drug pricing and payment reforms.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2018 · second_quarter · Q2
Issues relating to healthcare reform; Issues relating to solutions for opioid dependence; Issues relating to the FDA; Issues relating to prescription drug pricing; Public health and biodefense.
Tax issues related to biopharmaceutical manufacturers.
Medicare issues relating to biopharmaceutical manufacturers.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2018 · first_quarter · Q1
Issues relating to healthcare reform; Issues relating to solutions for opioid dependence; Issues relating to the FDA; Public health and biodefense.
Medicare issues relating to biopharmaceutical manufacturers.
Tax issues related to biopharmaceutical manufacturers.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2017 · fourth_quarter · Q4
Medicare issues relating to biopharmaceutical manufacturers.
Tax issues related to biopharmaceutical manufacturers.
Issues relating to healthcare reform; Issues relating to solutions for opioid dependence; Issues relating to the FDA; Public health and biodefense.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2017 · third_quarter · Q3
Health appropriations and budget issues.
Tax issues related to biopharmaceutical manufacturers.
H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, issues relating to drug importation; Affordable Care Act reform proposals; issues relating to the FDA.
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2017 · second_quarter · Q2
H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, issues relating to drug importation; Affordable Care Act reform proposals; issues relating to the FDA.
Tax issues related to biopharmaceutical manufacturers.
Health appropriations and budget issues.
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2017 · first_quarter · Q1
H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, issues relating to drug importation; Affordable Care Act reform proposals.
Health appropriations and budget issues.
Tax issues related to biopharmaceutical manufacturers.
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2016 · fourth_quarter · Q4
Issues relating to bio-preparedness; issues relating to innovation; H.R.6 - 21st Century Cures Act; FDA issues relating to biopharmaceuticals.
Issues relating to Medicare Part B, including the Medicare Program Part B Drug Payment Model proposed rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2016 · third_quarter · Q3
Issues relating to Medicare; issues relating to bio-preparedness; issues relating to innovation; H.R.6 - 21st Century Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC via REGENERON PHARMACEUTICALS, INC
2016 · third_quarter · RR
Issues relating to the biopharmaceutical sector, innovation, and health care manufacturing
Medicare Part D issues.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Medicare Part D issues.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Medicare Part D issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE